Xencor has been granted a patent for a bispecific binding agent that can treat cancer. The agent contains two binding domains, one specific to CLDN18.2 and the other to CD3. The agent consists of four polypeptide chains with specific amino acid sequences. GlobalData’s report on Xencor gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Xencor Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Xencor, Personalized cancer vaccines was a key innovation area identified from patents. Xencor's grant share as of September 2023 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Bispecific binding agent for treating cancer

Source: United States Patent and Trademark Office (USPTO). Credit: Xencor Inc

A recently granted patent (Publication Number: US11739145B2) describes a bispecific binding agent that has the ability to bind to two different targets simultaneously. The binding agent consists of four polypeptide chains and includes three binding domains. The first and second binding domains specifically bind to a target called human CLDN18.2, while the third binding domain binds to a target called human CD3.

The patent claims specify the amino acid sequences of the polypeptide chains that make up the bispecific binding agent. The first polypeptide chain has the amino acid sequence of SEQ ID NO: 73, the second polypeptide chain has the amino acid sequence of SEQ ID NO: 74, and the third and fourth polypeptide chains have the amino acid sequence of SEQ ID NO: 78.

The patent also includes claims related to nucleic acid molecules encoding the bispecific binding agent, as well as claims related to host cells and vectors containing these nucleic acid molecules.

Furthermore, the patent describes variants of the bispecific binding agent. These variants involve C-terminal truncations of the first and second polypeptide chains. Specifically, the C-terminal truncation variant of SEQ ID NO: 73 involves the deletion of lysine at position 447, while the C-terminal truncation variant of SEQ ID NO: 74 involves the deletion of lysine at position 720.

Overall, this patent provides protection for a bispecific binding agent that can simultaneously bind to human CLDN18.2 and human CD3. The patent covers the specific amino acid sequences of the polypeptide chains, as well as variants of these sequences. It also includes claims related to nucleic acid molecules, host cells, and vectors associated with the bispecific binding agent.

To know more about GlobalData’s detailed insights on Xencor, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies